Docetaxel Market To Reach $1.85 Billion By 2030 | CAGR: 5.75%

May 2025 | Report Format: Electronic (PDF)

Docetaxel Market Growth And Trends

The global docetaxel market size is anticipated to reach USD 1.85 billion by 2030, growing at a CAGR of 5.75% during the forecast period, according to a new report by Grand View Research, Inc. Despite moderate growth, the market remains sustained by the rising global cancer burden, particularly in breast, lung, and prostate cancers-diseases where docetaxel continues to be used as a first- or second-line treatment. While the increasing adoption of targeted therapies limits expansion, improved screening programs, heightened cancer awareness, and demand for cost-effective chemotherapy contribute to the drug’s relevance. From 2025 to 2030, the breast cancer segment is projected to grow at 5.69% CAGR, reaching USD 611.08 million, while hormone-refractory prostate cancer and gastric adenocarcinoma are forecast to grow at a moderate growth rate.

Clinical integration of docetaxel remains strong. For instance, in 2025, breast cancer cases in the U.S. are expected to surpass 319,000. With a 99% five-year survival when detected early, screening initiatives support consistent docetaxel use in metastatic and early-stage therapies. Similarly, high incidence of non-small cell lung cancer (NSCLC) and hormone-resistant prostate cancer supports sustained demand. Fragmentation is also increasing due to product launches by generics and specialty formulations. In February 2025, Zydus Lifesciences entered a U.S. commercialization agreement with Zhuhai Beihai Biotech for BEIZRAY-an albumin-based docetaxel formulation approved via the 505(b)(2) pathway in 2024. With an annual target volume of \~531,000 units, the drug avoids synthetic excipients to reduce side effects.

Moreover, pipeline data suggest continued development in combination regimens. Between 2027 and 2032, trials involving docetaxel with agents such as DS-1062a (Daiichi Sankyo), daraxonrasib (Revolution Medicines), capivasertib (AstraZeneca), and others target NSCLC, prostate, breast, and gastric cancers. These studies involve sponsors like Novartis, Sanofi, GSK, CSPC, and Mirati, indicating active engagement from global players.

Industry trends show innovation in delivery and formulation, such as oral and extended-release docetaxel, while barriers like bioequivalence testing and regulatory scrutiny moderate new entries. Despite the availability of generics, stringent standards and established competition shape the landscape. Overall, docetaxel remains a core component in oncology protocols, supported by global clinical use, ongoing pipeline interest, and evolving partnerships.

key Request a free sample copy or view report summary: Docetaxel Market Report

Docetaxel Market Report Highlights

Based on indication, breast cancer dominated the docetaxel industry, accounting for 33.11% of the revenue share in 2024. This growth is driven by high global prevalence, established treatment protocols, and strong clinical efficacy of docetaxel in therapy.
Based on distribution channel, hospital pharmacies led the market and accounted for a revenue share of 56.00% in 2024, due to their central role in managing cancer treatment protocols and administering chemotherapy.
Key market players include Phyton Biotech LLC, Rochem International Inc., Alchem International Pvt Ltd, LGM Pharma, and HRV Global Life Sciences.
In February 2025, Novo Nordisk announced the FDA has declared the Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer shortage over, confirming U.S. supply meets demand. The company invested USD 6.5 billion to expand production and launched the AI-powered Find My Meds app. Novo Nordisk warns against counterfeit drugs and emphasizes responsible use of its FDA-approved docetaxel medicines.